Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia
Status:
Not yet recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
300 patients will be randomly distributed into the control group (n=150) and the experimental
group(n=150). Patients will receive two cycles of induction chemotherapy. The control group
receives standard 3+7 induction regimen containing cytarabine (100mg/m2 d1-7) and
daunorubicin (60mg/m2 d1-3). The experimental group receives venetoclax combined with
intensive chemotherapy (3+7 induction regimen same as the control group). For each group,
patients who fail to achieve CR/CRi after two courses of induction therapy may receive
alternative therapy decided by their physicians. After CR/CRi achieved, subjects proceed
allo-transplantation or consolidation therapy according to their ELN risks: subjects in
favorable risk group should continue with chemotherapy; subjects in poor risk group should go
through transplantation; for subjects in intermediate risk group, those with suitable donors
can receive transplantation while others can continue with consolidation therapy. Subjects
receive 3 courses of intermediate-dose cytarabine (1.5g/m2 q12h d1, 3, 5) for age>55 years or
high dose cytarabine (3g/m2 q12h d1, 3, 5) for ageā¤ 55 years as consolidation therapy with
venetoclax in experimental group and without venetoclax in control group. After
consolidation, patients will be observed.